About Halozyme Therapeutics (NASDAQ:HALO)
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:HALO
- CUSIP: 40637H10
- Web: www.halozyme.com
Capitalization:- Market Cap: $2.51474 billion
- Outstanding Shares: 134,013,000
Average Prices:- 50 Day Moving Avg: $16.07
- 200 Day Moving Avg: $13.85
- 52 Week Range: $8.18 - $17.92
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -21.41
- P/E Growth: -2.50
Sales & Book Value:- Annual Revenue: $134.17 million
- Price / Sales: 17.75
- Book Value: $0.43 per share
- Price / Book: 41.33
Profitability:- EBITDA: ($95,850,000.00)
- Net Margins: -89.43%
- Return on Assets: -43.03%
Debt:- Debt-to-Equity Ratio: 2.85%
- Current Ratio: 4.13%
- Quick Ratio: 3.94%
Misc:- Average Volume: 1.26 million shs.
- Beta: 2.26
- Short Ratio: 33.39
Frequently Asked Questions for Halozyme Therapeutics (NASDAQ:HALO)
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.02. The company earned $33.80 million during the quarter, compared to the consensus estimate of $31.76 million. The business's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.21) EPS. View Halozyme Therapeutics' Earnings History.
When will Halozyme Therapeutics make its next earnings announcement?
Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?
7 brokerages have issued 1-year price objectives for Halozyme Therapeutics' stock. Their predictions range from $7.00 to $29.00. On average, they expect Halozyme Therapeutics' stock price to reach $16.71 in the next twelve months. View Analyst Ratings for Halozyme Therapeutics.
Are investors shorting Halozyme Therapeutics?
Halozyme Therapeutics saw a decrease in short interest during the month of September. As of September 29th, there was short interest totalling 13,893,994 shares, a decrease of 31.6% from the September 15th total of 20,302,599 shares. Based on an average trading volume of 1,910,880 shares, the days-to-cover ratio is presently 7.3 days. Approximately 11.3% of the shares of the company are short sold.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Sarepta Therapeutics (SRPT), AveXis (AVXS), Spark Therapeutics (ONCE), GW Pharmaceuticals PLC (GWPH), Aerie Pharmaceuticals (AERI), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Insmed (INSM), Acceleron Pharma (XLRN), Intercept Pharmaceuticals (ICPT) and NovoCure Limited (NVCR).
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Connie L. Matsui, Chairman of the Board
- Helen I Torley, President, Chief Executive Officer, Director
- Laurie D. Stelzer, Chief Financial Officer, Senior Vice President
- Mark J. Gergen J.D., Chief Operating Officer, Senior Vice President
- Harry J. Leonhardt Esq., Senior Vice President, Chief Compliance Officer, General Counsel
- Athena M. Countouriotis M.D., Senior Vice President, Chief Medical Officer
- Jean-Pierre Bizzari M.D., Independent Director
- James M. Daly, Independent Director
- Jeffrey William Henderson, Independent Director
- Kenneth J. Kelley, Independent Director
Who owns Halozyme Therapeutics stock?
How do I buy Halozyme Therapeutics stock?
Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of Halozyme Therapeutics stock can currently be purchased for approximately $17.77.
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.43) |
| Consensus Price Target: | $16.71 (5.94% downside) |
Consensus Price Target History for Halozyme Therapeutics (NASDAQ:HALO)
Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/16/2017 | Piper Jaffray Companies | Boost Price Target | Overweight -> Overweight | $26.00 -> $29.00 | N/A |  |
| 9/15/2017 | BMO Capital Markets | Boost Price Target | Market Perform | $14.00 -> $15.00 | Medium | |
| 9/15/2017 | Deutsche Bank AG | Boost Price Target | Buy | $20.00 | Low | |
| 8/10/2017 | Jefferies Group LLC | Reiterated Rating | Underperform | $6.75 -> $7.00 | High | |
| 7/26/2017 | Canaccord Genuity | Set Price Target | Buy | $16.00 | High | |
| 6/23/2017 | Barclays PLC | Reiterated Rating | Overweight | $16.00 | Low | |
| 1/6/2017 | Citigroup Inc. | Downgrade | Buy -> Neutral | | N/A | |
| 9/8/2016 | Wells Fargo & Co | Reiterated Rating | Buy | | N/A | |
| 3/9/2016 | JMP Securities | Lower Price Target | Market Outperform | $22.00 -> $20.00 | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for Halozyme Therapeutics (NASDAQ:HALO)Earnings History by Quarter for Halozyme Therapeutics (NASDAQ HALO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | $0.06 | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.25) | ($0.23) | $31.76 million | $33.80 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.25) | ($0.26) | $30.79 million | $29.60 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.30) | ($0.21) | $37.94 million | $39.00 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.27) | ($0.23) | $34.43 million | $31.90 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.27) | ($0.21) | $29.94 million | $33.30 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.20) | ($0.16) | $29.65 million | $42.50 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.08) | $0.03 | $37.06 million | $52.20 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.16) | ($0.19) | $24.01 million | $20.80 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.09) | $0.02 | $24.84 million | $43.40 million | View | Listen | |
| 5/11/2015 | Q115 | ($0.13) | ($0.12) | $19.40 million | $18.70 million | View | Listen | |
| 3/2/2015 | Q414 | ($0.07) | ($0.04) | $25.60 million | $30.38 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.14) | ($0.16) | $16.50 million | $14.60 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.18) | ($0.13) | $13.71 million | $18.40 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.14) | ($0.22) | $13.37 million | $12.00 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.17) | ($0.19) | $21.80 million | $12.50 million | View | N/A | |
| 11/8/2013 | Q313 | ($0.15) | ($0.17) | $14.62 million | $16.00 million | View | N/A | |
| 8/7/2013 | Q2 2013 | ($0.13) | ($0.13) | $11.29 million | $14.50 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.15) | ($0.17) | $7.05 million | $11.83 million | View | N/A | |
| 2/25/2013 | Q4 2012 | ($0.16) | ($0.04) | $7.32 million | $21.80 million | View | N/A | |
| 11/8/2012 | Q312 | ($0.13) | ($0.18) | $6.09 million | $5.33 million | View | N/A | |
| 8/6/2012 | | ($0.15) | ($0.13) | | | View | N/A | |
| 5/7/2012 | | ($0.11) | $0.14 | | | View | N/A | |
| 3/9/2012 | | ($0.16) | ($0.18) | | | View | N/A | |
| 11/7/2011 | | ($0.03) | $0.05 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)2017 EPS Consensus Estimate: ($1.07)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q2 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q3 2017 | 1 | ($0.27) | ($0.27) | ($0.27) |
| Q4 2017 | 1 | ($0.26) | ($0.26) | ($0.26) |
(Data provided by Zacks Investment Research)
Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Halozyme Therapeutics (NASDAQ:HALO)Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 85.06%
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/20/2015 | Laurie Stelzer | CFO | Buy | 10,000 | $17.24 | $172,400.00 | |
| 6/18/2015 | Kenneth J Kelley | Director | Sell | 20,000 | $21.00 | $420,000.00 | |
| 9/16/2014 | David A Ramsay | CFO | Buy | 25,000 | $8.90 | $222,500.00 | |
| 9/16/2014 | Helen Torley | CEO | Buy | 50,000 | $8.92 | $446,000.00 | |
| 8/19/2014 | John Stuart Patton | Director | Sell | 75,000 | $9.96 | $747,000.00 | |
| 5/15/2014 | Robert Engler | Director | Sell | 126,700 | $7.56 | $957,852.00 | |
| 9/16/2013 | John Stuart Patton | Director | Sell | 75,000 | $9.13 | $684,750.00 | |
| 8/19/2013 | H. Michael Shepard | VP | Sell | 10,000 | $7.11 | $71,100.00 | |
| 8/14/2013 | Kathryn Falberg | Director | Buy | 100,000 | $6.82 | $682,000.00 | |
| 11/29/2012 | Robert Engler | Director | Buy | 15,000 | $5.57 | $83,550.00 | |
| 11/14/2012 | James P Shaffer | VP | Buy | 20,000 | $5.22 | $104,400.00 | |
| 11/13/2012 | Kathryn E Falberg | Director | Buy | 50,000 | $5.21 | $260,500.00 | |
| 8/27/2012 | Kenneth J Kelley | Director | Buy | 20,000 | $5.70 | $114,000.00 | |
| 8/13/2012 | Gregory Ian Frost | CEO | Buy | 2,000 | $5.50 | $11,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Halozyme Therapeutics (NASDAQ:HALO)
Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Halozyme Therapeutics, Inc. : October 18, 2017
finance.yahoo.com - October 19 at 1:41 AM |
| 3 Drug Stocks Hitting 52-Week Highs: Are They Buys?
finance.yahoo.com - October 17 at 3:18 PM |
 | Halozyme Therapeutics (HALO) Commences Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma & Gallbladder Cancer Patients
www.streetinsider.com - October 16 at 4:01 PM |
| Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients
finance.yahoo.com - October 16 at 4:01 PM |
 | Piper Jaffray Companies Boosts Halozyme Therapeutics, Inc. (HALO) Price Target to $29.00
www.americanbankingnews.com - October 16 at 11:06 AM |
| Halozyme Therapeutics, Inc. (HALO) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 13 at 1:32 AM |
| Halozyme Therapeutics, Inc. (HALO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 11 at 8:08 PM |
| Halozyme to Host Third Quarter 2017 Financial Results Conference Call
finance.yahoo.com - October 10 at 6:49 PM |
| Halozyme Therapeutics, Inc. (HALO) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 6 at 11:14 PM |
| ETFs with exposure to Halozyme Therapeutics, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 7:50 PM |
| Halozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 2:00 PM |
| $34.27 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - October 2 at 11:50 AM |
 | Halozyme Therapeutics (HALO) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 5:16 PM |
 | Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions? - Nasdaq
www.nasdaq.com - September 22 at 11:18 PM |
| Halozyme Therapeutics: Updates To Thesis - Seeking Alpha
seekingalpha.com - September 22 at 6:14 PM |
| Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - September 22 at 1:10 PM |
| Halozyme Therapeutics, Inc. to Post FY2019 Earnings of ($0.62) Per Share, Jefferies Group Forecasts (HALO)
www.americanbankingnews.com - September 18 at 9:34 AM |
| Halozyme Therapeutics, Inc. (HALO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 9:04 PM |
 | Halozyme to license drug delivery tech to Roche, Bristol-Myers - Reuters
www.reuters.com - September 16 at 1:06 AM |
| Halozyme Therapeutics, Inc. (HALO) PT Raised to $20.00 at Deutsche Bank AG
www.americanbankingnews.com - September 15 at 11:12 PM |
| Stocks To Watch: Halozyme Therapeutics Sees Relative Strength Rating Rise To 90
finance.yahoo.com - September 15 at 8:03 PM |
| Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2%
finance.yahoo.com - September 15 at 8:03 PM |
| Halozyme Therapeutics, Inc. (HALO) Price Target Increased to $15.00 by Analysts at BMO Capital Markets
www.americanbankingnews.com - September 15 at 2:34 PM |
 | Halozyme Increases 2017 Financial Guidance - PR Newswire (press release)
www.prnewswire.com - September 15 at 1:06 AM |
| Halozyme Therapeutics Presents at 2017 Wells Fargo Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - September 15 at 1:06 AM |
 | Halozyme's stock soars after Bristol-Myers license deal - MarketWatch
www.marketwatch.com - September 15 at 1:06 AM |
 | Halozyme Therapeutics Wins Big on Roche License Agreement - 24/7 Wall St.
247wallst.com - September 15 at 1:06 AM |
 | Here's Why Halozyme Therapeutics, Inc. Is Soaring Today - Motley Fool
www.fool.com - September 15 at 1:06 AM |
| Bristol-Myers Partners With Halozyme; Gains Access To ENHANZE Technology
www.nasdaq.com - September 14 at 8:04 PM |
| Halozyme Increases 2017 Financial Guidance
finance.yahoo.com - September 14 at 8:04 PM |
| Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
finance.yahoo.com - September 14 at 8:04 PM |
| Halozyme's stock soars after Bristol-Myers license deal
finance.yahoo.com - September 14 at 8:04 PM |
| Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
finance.yahoo.com - September 14 at 8:04 PM |
| Halozyme to license drug delivery tech to Roche, Bristol-Myers
finance.yahoo.com - September 14 at 8:04 PM |
| Here's Why Halozyme Therapeutics, Inc. Is Soaring Today
finance.yahoo.com - September 14 at 8:04 PM |
| Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today
finance.yahoo.com - September 14 at 8:04 PM |
| Piper Jaffray Companies Boosts Halozyme Therapeutics, Inc. (HALO) Price Target to $26.00
www.americanbankingnews.com - September 14 at 1:40 PM |
| Here's Why Halozyme Therapeutics, Inc. Is Soaring Today
www.fool.com - September 14 at 12:46 PM |
| Analyzing Halozyme Therapeutics (HALO) & its Rivals
www.americanbankingnews.com - September 10 at 8:24 PM |
| Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : September 1, 2017
finance.yahoo.com - September 1 at 7:42 PM |
| Stocks Generating Improved Relative Strength: Halozyme Therapeutics
finance.yahoo.com - August 31 at 5:19 AM |
| Halozyme Therapeutics To Present At Upcoming Healthcare Conferences - PR Newswire (press release)
www.prnewswire.com - August 26 at 11:39 PM |
| Halozyme Therapeutics, Inc. (HALO) Expected to Announce Quarterly Sales of $33.01 Million
www.americanbankingnews.com - August 25 at 4:54 AM |
| Halozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 8:44 PM |
| See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
finance.yahoo.com - August 11 at 7:46 PM |
| Jefferies Group Comments on Halozyme Therapeutics, Inc.'s Q3 2017 Earnings (HALO)
www.americanbankingnews.com - August 11 at 8:56 AM |
| Halozyme Therapeutics, Inc. (HALO) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - August 10 at 12:47 PM |
| Edited Transcript of HALO earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 10 at 5:36 AM |
| Halozyme Therapeutics, Inc. (HALO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - August 9 at 10:05 PM |
| Halozyme Reports Second Quarter 2017 Results - PR Newswire (press release)
www.prnewswire.com - August 9 at 7:30 PM |
Halozyme Therapeutics (HALO) Chart for Friday, October, 20, 2017
